Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets

Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06% are bioequivalent to Atrovent nasal spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.

Ipratropium bromide nasal solution (nasal spray) 0.03% is indicated for the symptomatic relief of rhinorrhoea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium bromide nasal solution (nasal spray) 0.06% is indicated for the symptomatic relief of rhinorrhoea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.

Ipratropium bromide nasal solution (Atrovent) had estimated annual sales of USD 63 million in the US (IQVIA MAT May 2025).